Tongyao Liu

This inventor holds 16 USPTO granted patents and 19 published patent applications, plus 1 CIPO patent and 11 EPO patents. Top assignees: Bioverativ Therapeutics Inc., Puget Sound Blood Center. Active years: 2018-2026.

USPTO Granted Patents = 16 (Patent Applications = 19)

% Patents Active = 93.8

CIPO Patents = 1 (Patent Applications = 10)

EPO Patents = 11 (Patent Applications = 19)

Average Co-Inventor Count = 4.6

ph-index = 4

Forward Citations = 59(Granted Patents)

Company Filing History:

16 out of 76

Bioverativ Therapeutics Inc.

patents

3 out of 8

Puget Sound Blood Center

patents

where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12617839 - Factor VIII chimeric proteins and uses thereof (2026-05-05),

2. 12371747 - Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy (2025-07-29),

3. 12364774 - Nucleic acid molecules and uses thereof for non-viral gene therapy (2025-07-22),

4. 12275970 - Optimized factor IX gene (2025-04-14),

5. 12168776 - Nucleic acid molecules and uses thereof (2024-12-17),

6. 11753461 - Optimized factor VIII genes (2023-09-12),

7. 11370827 - Chimeric factor VIII polypeptides and uses thereof (2022-06-28),

8. 11286528 - Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy (2022-03-29),

9. 11192936 - Factor VIII chimeric proteins and uses thereof (2021-12-07),

10. 11091534 - Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof (2021-08-17),

11. 11008561 - Optimized factor IX gene (2021-05-18),

12. 10745680 - Factor IX fusion proteins and methods of making and using same (2020-08-18),

13. 10548953 - Factor VIII-XTEN fusions and uses thereof (2020-02-04),

14. 10421798 - Factor VIII compositions and methods of making and using same (2019-09-24),

15. 10221455 - Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy (2019-03-05),

Title: Innovations and Contributions of Inventor Tongyao Liu

Introduction

Tongyao Liu is a prominent inventor based in Lexington, MA, known for his significant contributions to the field of biomedical research. With a total of 15 patents to his name, Liu has made remarkable advancements in therapies related to coagulation and gene therapy. His work has the potential to greatly impact the treatment of various medical conditions.

Latest Patents

Among his latest patents, Liu has developed methods aimed at reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy. This patent provides innovative methods for administering chimeric and hybrid Factor VIII polypeptides, which are crucial for promoting coagulation and inducing immune tolerance to FVIII. Additionally, he has patented nucleic acid molecules designed for non-viral gene therapy, which include genetic cassettes encoding target sequences such as miRNAs and therapeutic proteins. These advancements are essential for treating metabolic disorders of the liver and other conditions.

Career Highlights

Throughout his career, Tongyao Liu has worked with notable companies such as Bioverativ Therapeutics Inc. and Puget Sound Blood Center. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research in the field of therapeutics.

Collaborations

Liu has collaborated with esteemed colleagues, including Robert T Peters and Haiyan Jiang, to further enhance his research and development efforts. These collaborations have played a vital role in advancing his innovative projects.

Conclusion

Tongyao Liu's contributions to the field of biomedical research through his patents and collaborations highlight his role as a leading inventor. His work continues to pave the way for new therapeutic approaches that can significantly improve patient outcomes.